Inventor · disambiguated record
Uwe Haberkorn
Also filed as: HABERKORN UWE
20 granted patents·16 pending applications·82 citations·filing 2001–2024
93Inventor score
Files withDEUTSCHES KREBSFORSCH13UNIV HEIDELBERG5UNIV HEIDELBERG RUPRECHT KARLS4MIER WALTER3AMCURE GMBH2
Top patents by PatentIndex Score
36 records- 0196US10398791B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 3, 2019·22 cites·30 claims
- 0294US10471160B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Nov 12, 2019·16 cites·28 claims
- 0393US10815200B218F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Oct 27, 2020·8 cites·8 claims
- 0491US10016519B218F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2017·Granted Jul 10, 2018·8 cites·18 claims
- 0587US9078929B2ε-Polylysine conjugates and the use thereofKUEBELBECK ARMIN·Filed 2010·Granted Jul 14, 2015·16 cites·17 claims
- 0683US12054458B218F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2023·Granted Aug 6, 2024·0 cites·12 claims
- 0781US11020493B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2019·Granted Jun 1, 2021·1 cites·7 claims
- 0879US11452786B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 27, 2022·1 cites·66 claims
- 0979US2025127937A1Fap inhibitorUNIV HEIDELBERG·Filed 2024·Application pending·0 cites
- 1076US10980901B2Treatment of PMSA expressing cancersTHE EUROPEAN ATOMIC ENERGY COMMUNITY EURATOM REPRESENTED BY THE EUROPEAN COMMISSION·Filed 2016·Granted Apr 20, 2021·4 cites·13 claims
- 1174US10253099B2Conjugates of proteins and multivalent cell-penetrating peptides and their usesUNIV HEIDELBERG RUPRECHT KARLS·Filed 2013·Granted Apr 9, 2019·3 cites·20 claims
- 1274US2025057993A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancersUNIV HEIDELBERG·Filed 2024·Application pending·0 cites
- 1371US10406246B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2014·Granted Sep 10, 2019·1 cites·11 claims
- 1471US2019336622A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Application pending·0 cites
- 1571US2023112012A1Fap inhibitorUNIV HEIDELBERG·Filed 2022·Application pending·0 cites
- 1670US9808535B2Conjugates for protection from nephrotoxic active substancesMERCK PATENT GMBH·Filed 2014·Granted Nov 7, 2017·1 cites·7 claims
- 1769US9868768B2Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as vehicles for the specific delivery of compounds to the liverMIER WALTER·Filed 2009·Granted Jan 16, 2018·1 cites·20 claims
- 1868US12156920B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2022·Granted Dec 3, 2024·0 cites·22 claims
- 1968US2021053922A118f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 2065US2021038749A1Fap inhibitorUNIV HEIDELBERG·Filed 2019·Application pending·0 cites
- 2162US2016228587A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2016·Application pending·0 cites
- 2261US2021393809A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancersUNIV HEIDELBERT·Filed 2019·Application pending·0 cites
- 2355US2009130020A1Diagnostic agents for positron emission imaging using f-18 radio-labeled amino-alcoholsLEHMANN LUTZ·Filed 2008·Application pending·0 cites
- 2453US10413614B2Conjugates for protection from nephrotoxic active substancesMERCK PATENT GMBH·Filed 2017·Granted Sep 17, 2019·0 cites·8 claims
- 2552US2020283503A1Cd44v6-derived cyclic peptides for treating cancers and angiogenesis related diseasesAMCURE GMBH·Filed 2020·Application pending·0 cites
- 2650US2022118121A1Prostate specific membrane antigen (psma) ligands with improved tissue specificityUNIV HEIDELBERG RUPRECHT KARLS·Filed 2020·Application pending·0 cites
- 2749US10703796B2CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseasesAMCURE GMBH·Filed 2015·Granted Jul 7, 2020·0 cites·19 claims
- 2849US2007202047A1Polyamine-substituted ligands for use as contrast agentsWOLF MARKUS·Filed 2007·Application pending·0 cites
- 2945US11638765B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2018·Granted May 2, 2023·0 cites·41 claims
- 3045US2024238460A1Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereofTELIX PHARMACEUTICALS INNOVATIONS PTY LTD·Filed 2022·Application pending·0 cites
- 3142US2020131227A1Polypeptide with tumour binding activityUNIV HEIDELBERG RUPRECHT KARLS·Filed 2018·Application pending·0 cites
- 3242US2001029035A1Oligonucleotide conjugatesFiled 2001·Application pending·0 cites
- 3340US10653796B2Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromoleculesUNIV HEIDELBERG·Filed 2016·Granted May 19, 2020·0 cites·13 claims
- 3440US10363323B2Hydrophobic modified peptides for liver specific diagnosisMIER WALTER·Filed 2012·Granted Jul 30, 2019·0 cites·40 claims
- 3539US2019351069A1Coating of Nanoparticle Surfaces with Cyclopeptides for Improving Delivery of Agents Via the Oral RouteUNIV HEIDELBERG RUPRECHT KARLS·Filed 2017·Application pending·0 cites
- 3636US10513539B2Hydrophobic modified peptides and their use for liver specific targetingMIER WALTER·Filed 2012·Granted Dec 24, 2019·0 cites·38 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →